Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efprezimod alfa (Primary)
  • Indications COVID-19 respiratory infection; Respiratory insufficiency
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SAC-COVID
  • Sponsors OncoImmune

Most Recent Events

  • 01 May 2022 Primary endpoint (Time to Improvement in Coronavirus Disease 2019 (COVID-19) Clinical Status) has been met as per results published in The Lancet Infectious Diseases
  • 01 May 2022 Results published in The Lancet Infectious Diseases
  • 15 Apr 2021 According to a Merck and Co media release, given timeline and these technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Mercks resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck has determined to discontinue development of MK-7110 for COVID-19.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top